Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Fukujin Ties Up with Kobayashi Daiyakubo
September 3, 2001
- Employees' Health Insurance Societies Have Assets of \5.2 Trillion: JMA
September 3, 2001
- Takeda Enters Top 10: Corporate Income Ranking
September 3, 2001
- RESEARCH AND DEVELOPMENT NEWS IN BRIEF
September 3, 2001
- Zeria Licenses in Visicol from InKine
September 3, 2001
- World News in Brief
September 3, 2001
- IPLS to Focus on Changing Licensing Business -2-
September 3, 2001
- IPLS to Focus on Changing Licensing Business -1-
September 3, 2001
- Hospital Chains Will Increase: Ihoken
September 3, 2001
- Air Liquid Japan: Healthcare Accounts for 8% of Total Sales
September 3, 2001
- REGULATORY NEWS IN BRIEF
September 3, 2001
- Zimmer of US Listed on NYSE
September 3, 2001
- Medical Costs at Medical Institutions Down 1.9%
September 3, 2001
- Toshiba: High-speed Multislice CT Scanners
September 3, 2001
- Minister-backed Panel to Propose Policies to Promote Drug Discovery
September 3, 2001
- Antacids Are Most Expensive in Tokyo: Inter-city Comparison of OTC Drug Prices
September 3, 2001
- PMSB Considers Introduction of Drug Master File System
September 3, 2001
- Kirin-do to Strengthen Dispensing Function
September 3, 2001
- ADR Reports on 6 Drugs Including Temocapril HCl Published
September 3, 2001
- Jovi to Tie Up with CGC Japan
September 3, 2001
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…